Recombinant Human Palmitoyltransferase ZDHHC9 (ZDHHC9)

What is ZDHHC9 and what is its primary biochemical function?

ZDHHC9 is one of 23 human DHHC acyltransferases that catalyze protein S-acylation, a reversible lipid post-translational modification that regulates protein stability, membrane association, and localization. This enzyme specifically catalyzes the transfer of acyl groups (commonly palmitate) to protein substrates, with Ras proteins being well-established targets. The palmitoylation process occurs through an enzyme-palmitoyl intermediate formation followed by transfer of the palmitoyl moiety to a protein substrate . ZDHHC9 function is particularly important in the brain, with its dysregulation associated with X-linked intellectual disability (XLID) and increased epilepsy risk .

How does the ZDHHC9-GCP16 complex form and function?

ZDHHC9 requires association with an accessory protein, GCP16, to achieve proper enzymatic function. Recent research demonstrates that GCP16 stabilizes ZDHHC9 by preventing its aggregation through protein complex formation. Using size-exclusion chromatography and palmitoyl acyltransferase assays, researchers have confirmed that only properly folded ZDHHC9-GCP16 complexes are enzymatically active in vitro . This interaction is critical for maintaining the structural integrity and functional capacity of ZDHHC9.

What structural features are essential for ZDHHC9 function?

A conserved C-terminal cysteine motif (CCM) is required for ZDHHC9 and GCP16 complex formation and enzymatic activity. This motif is present across the DHHC9 subfamily members (DHHC14, -18, -5, and -8). Co-expression studies have shown that GCP16 improves protein stability of all DHHCs containing this CCM . Additionally, the DHHC domain itself is critical for catalytic activity, with DHHC to DHHA mutations abolishing enzymatic function, as demonstrated in complementation assays .

How do mutations in ZDHHC9 affect protein function and lead to intellectual disability?

Multiple ZDHHC9 mutations have been associated with X-linked intellectual disability (XLID). These pathogenic variants include missense mutations R148W, P150S, and R96W, as well as a non-sense mutation terminating at R298. Experimental investigations have revealed that these mutations result in:

• Reduced steady-state levels of autopalmitoylated ZDHHC9

• Increased protein aggregation and reduced monodispersity

• Compromised ZDHHC9-GCP16 complex formation

Biophysical characterization demonstrates that XLID-associated mutations affect the autopalmitoylation step of the reaction by lowering the steady-state amount of palmitoyl-ZDHHC9 intermediate, though the specific mechanisms may differ between mutations .

What phenotypes are observed in Zdhhc9 knockout mice?

Zdhhc9 knockout mice display significant abnormalities in oligodendrocyte morphology and myelination despite grossly normal oligodendrocyte development. Key phenotypic findings include:

• Heterogeneous thickness of oligodendrocyte processes with numerous spheroid-like swellings

• Abnormal patterns of axonal myelination with many large axons remaining unmyelinated while small diameter axons (<0.5 μm) appear hypermyelinated

• Altered g-ratios indicating irregular myelin thickness relative to axon diameter

• Decreased density of myelinated axons and disrupted myelin compaction in the corpus callosum

• Changes in oligodendrocyte subtype proportions with decreased MOL2/3 cells (enriched for myelination genes) and increased MOL5/6 cells (enriched for cell adhesion and synaptic genes)

These findings establish ZDHHC9 as essential for proper oligodendrocyte function and myelination.

How does ZDHHC9 deficiency impact gene expression in oligodendrocytes?

RNA sequencing and proteomic analyses of Zdhhc9 knockout mice have revealed significant alterations in gene expression profiles. Specifically, transcriptomic analysis shows:

• Reduced expression of genes essential for lipid metabolism, cholesterol synthesis, and myelin compaction

• Upregulation of genes enriched in oligodendrocyte precursor cells (OPCs)

• Downregulation of genes enriched in MOL2/3 subtype cells

• Increased expression of marker genes like Svep1, which is highly enriched in MOL6 oligodendrocytes

These expression changes reflect significant disruptions in the molecular programs governing oligodendrocyte differentiation and myelination capacity.

What techniques can be used to assess ZDHHC9 enzymatic activity?

Several complementary approaches can be employed to analyze ZDHHC9 activity:

• Radiometric assays: Using H-Ras substrate and [³H]-palmitoyl CoA, followed by quantification via liquid scintillation spectroscopy and fluorography. This method allows direct measurement of both autopalmitoylation and substrate palmitoylation .

• Yeast-based complementation assays: Testing the in vivo function of ZDHHC9 variants by assessing their ability to complement Ras-related phenotypes in yeast. Typically performed using serial dilutions of transformed cells on selective media containing 5′-fluoroorotic acid .

• Protein complex formation analysis: Since ZDHHC9 activity requires proper complex formation with GCP16, techniques assessing this interaction (such as co-immunoprecipitation or size-exclusion chromatography) provide indirect measures of functional capacity .

How can researchers evaluate ZDHHC9 protein folding and stability?

The following techniques have proven valuable for assessing ZDHHC9 folding states and stability:

• Size-exclusion chromatography (SEC): Distinguishes between aggregated (non-functional) and properly folded (functional) states of ZDHHC9 .

• Fluorescence-detection size-exclusion chromatography (FSEC): Provides higher sensitivity for monitoring protein behavior and complex formation with GCP16 .

• Co-expression studies: Evaluating how co-expression with GCP16 affects ZDHHC9 stability and folding through comparative SEC profiles .

The table below summarizes the comparison between wild-type and mutant ZDHHC9 folding states:

What approaches are effective for studying the impact of ZDHHC9 on myelination?

Multiple complementary techniques have been employed to characterize myelination defects in Zdhhc9 knockout models:

• Electron microscopy (EM): Provides high-resolution visualization of myelin ultrastructure, enabling quantification of myelinated vs. unmyelinated axons and assessment of myelin thickness .

• G-ratio analysis: Quantifies the ratio of axon diameter to total fiber diameter, offering a standardized measure of myelin thickness. In Zdhhc9 KO mice, small diameter axons show altered g-ratios indicating hypermyelination .

• Sparse genetic labeling: Using fluorescent reporters to visualize individual oligodendrocyte morphology, revealing abnormal process thickness and spheroid-like swellings in Zdhhc9 KO mice .

• Bioinformatic deconvolution methods: Tools like Bisque can be applied to bulk RNA-seq data to estimate changes in cell type proportions, revealing shifts in oligodendrocyte subtype distribution .

How do different ZDHHC9 mutations produce similar phenotypes through distinct mechanisms?

While ZDHHC9 mutations associated with XLID produce similar clinical presentations, research suggests they operate through different molecular mechanisms. The R148W and P150S mutations specifically affect the autopalmitoylation step of the reaction, reducing the steady-state level of palmitoyl-ZDHHC9 intermediate . Other mutations like R96W severely compromise GCP16 interaction, with co-expression providing minimal rescue of protein folding . Understanding these distinct mechanisms requires:

• Structure-function analysis correlating mutation position with specific biochemical defects

• Comparative enzymology assessing each step of the palmitoylation reaction

• Analysis of substrate specificity alterations in different mutants

• Assessment of protein-protein interactions beyond GCP16

This mechanistic diversity has important implications for developing targeted therapeutic approaches.

What is the specificity of accessory protein interactions among DHHC subfamily members?

The ZDHHC9 subfamily (DHHC9, -14, -18, -5, and -8) shares the conserved C-terminal cysteine motif (CCM) required for accessory protein interaction. Research indicates differential specificity in these interactions:

• GCP16 improves protein stability for DHHC9, DHHC14, and DHHC18, and is required for their enzymatic activity

• GOLGA7B, which shares 75% sequence identity with GCP16, selectively improves protein stability of DHHC5 and DHHC8, but not other subfamily members

This suggests evolutionary divergence in accessory protein requirements, potentially enabling specialized regulation and function of different DHHC enzymes. Further research into the structural basis of these selective interactions could provide insights into palmitoylation regulation in different cellular contexts.

How does ZDHHC9 deficiency disrupt oligodendrocyte subtype determination?

Recent single-cell transcriptomic analyses reveal that Zdhhc9 knockout alters oligodendrocyte subtype proportions, with decreased myelination-associated MOL2/3 cells and increased MOL5/6 cells . This raises fundamental questions about the role of protein palmitoylation in cell fate decisions:

• What are the key ZDHHC9 substrates in each oligodendrocyte subtype?

• How does palmitoylation influence transcriptional networks governing subtype specification?

• Are the observed subtype shifts a direct result of ZDHHC9 loss or compensatory responses?

Addressing these questions will require integration of proteomics to identify ZDHHC9 substrates, transcriptomic analysis across developmental timepoints, and advanced lineage tracing studies.

What techniques can overcome limitations in visualizing ZDHHC9-mediated palmitoylation dynamics?

Current methodologies for studying protein palmitoylation often provide static snapshots rather than dynamic information. Emerging approaches to address this limitation include:

• Bioorthogonal labeling strategies using alkyne-palmitate analogs coupled with click chemistry

• Proximity-based enzymatic tagging of palmitoylated proteins

• FRET-based sensors for real-time visualization of palmitoylation events

• Advanced mass spectrometry approaches for site-specific and quantitative palmitoylation analysis

These methods would enable researchers to track palmitoylation dynamics in living cells and potentially correlate these events with changes in subcellular localization or protein function.

How can researchers address the technical challenges of studying white matter defects in ZDHHC9 models?

The complex three-dimensional architecture of myelinated axons presents significant technical challenges. Current electron microscopy approaches typically provide two-dimensional cross-sections, which may not fully capture the spatial heterogeneity of myelination defects in Zdhhc9 knockout mice. As noted in the literature, "EM-based reconstruction in 3 dimensions would reveal regions of both hypo- and hypermyelination of individual callosal axons in Zdhhc9 KO mice" . Additional approaches to overcome these limitations include:

• Serial block-face scanning electron microscopy for 3D reconstruction

• Advanced diffusion MRI techniques for non-invasive assessment of white matter integrity

• Live imaging of myelination using zebrafish or ex vivo slice culture models

• Correlative light and electron microscopy to link molecular markers with ultrastructural features

These approaches would provide a more comprehensive understanding of how ZDHHC9 deficiency affects myelination across different spatial scales.